Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0
作者：
Yang, J. [1 ]
Cheng, Y. [2 ]
Murakami, H. [3 ]
Yang, P-C. [1 ]
He, J. [4 ]
Nakagawa, K. [5 ]
Kang, J. H. [6 ]
Kim, J-H. [7 ]
Hozak, R. [8 ]
Nguyen, T. [9 ]
Wang, X. [10 ]
Enatsu, S. [11 ]
Puri, T. [12 ]
Orlando, M. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan
[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China
[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea
[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA
[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China
[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan
[12] Eli Lilly & Co, Med Affairs, Gurgaon, India
[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1240P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Chaplin, Marty
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
  • [22] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial
    Kato, Terufumi
    Seto, Takashi
    Nishio, Makoto
    Goto, Koichi
    Atagi, Shinji
    Hosomi, Yukio
    Yamamoto, Noboru
    Hida, Toyoaki
    Maemondo, Makoto
    Nakagawa, Kazuhiko
    Nagase, Seisuke
    Okamoto, Isamu
    Yamanaka, Takeharu
    Harada, Ryosuke
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] POPULATION BASED EVALUATION OF CHEMOTHERAPY USE AFTER FIRST LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Mariano, C.
    Bosdet, I.
    Ionescu, D.
    Karsan, A.
    Sun, S.
    Murray, N.
    Melosky, B.
    Laskin, J.
    Ho, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 412 - 412
  • [25] First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 370 - 379
  • [26] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Douillard, Jean-Yves
    Ostoros, Gyula
    Cobo, Manuel
    Ciuleanu, Tudor
    Mccormack, Rose
    Webster, Alan
    Milenkova, Tsveta
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1194 - S1195
  • [27] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, de Lima G.
    VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
  • [28] Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    Chen, Kuan-Yu
    Yang, Chih-Hsin
    Yu, Chong-Jen
    Yang, Pan-Chyr
    MEDICINE, 2011, 90 (03) : 159 - 167
  • [29] Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
    Yoshioka, Hiroshige
    Mitsudomi, Tetsuya
    Morita, Satoshi
    Yatabe, Yasushi
    Negoro, Shunichi
    Okamoto, Isamu
    Seto, Takashi
    Satouchi, Miyako
    Tada, Hirohito
    Hirashima, Tomonori
    Asami, Kazuhiro
    Katakami, Nobuyuki
    Takada, Minoru
    Shibata, Kazuhiko
    Kudoh, Shinzoh
    Shimizu, Eiji
    Saito, Hiroshi
    Toyooka, Shinichi
    Nakagawa, Kazuhiko
    Fukuoka, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345